Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial-Reference-Cited by-同舟云学术

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial

Published:2018-05-31 Issue:6 Volume:109 Page:1930-1938
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Akamatsu Hiroaki¹^ORCID,Katakami Nobuyuki²,Okamoto Isamu³,Kato Terufumi⁴,Kim Young Hak⁵,Imamura Fumio⁶,Shinkai Masaharu⁷,Hodge Rachel A.⁸,Uchida Hirohiko⁹,Hida Toyoaki¹⁰

Affiliation:

1. Third Department of Internal Medicine; Wakayama Medical University; Wakayama Japan

2. Institute of Biomedical Research and Innovation; Kobe Japan

3. Research Institute for Diseases of the Chest; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

4. Kanagawa Cardiovascular and Respiratory Center; Yokohama Japan

5. Graduate School of Medicine; Kyoto University; Kyoto Japan

6. Osaka International Cancer Institute; Osaka Japan

7. Yokohama City University Medical Center; Yokohama Japan

8. AstraZeneca; Royston, Hertfordshire UK

9. AstraZeneca; Osaka Japan

10. Aichi Cancer Center Hospital; Nagoya Japan

Funder

AstraZeneca

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13623/fullpdf

Reference23 articles.

1. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016;Tan;J Thorac Oncol,2016

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N Engl J Med,2005

5. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatic mutation: Pharmacogenomics in oncology care;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

2. Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma;PLOS ONE;2023-11-16

3. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study;Cancer Research and Treatment;2023-10-15

4. Kết quả điều trị bước 2 ung thư phổi không tế bào nhỏ có đột biến T790M thứ phát bằng Osimertinib tại bệnh viện ung bướu Đà Nẵng;Journal of Clinical Medicine- Hue Central Hospital;2023-08-19

5. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study;Journal of Cancer Research and Clinical Oncology;2023-06-14